الفهرس 
A pharmaceutical study on a colon targeted drug delivery system
ContentOnly 14 pages are availabe for public view
 |  | from | 217 |  |  |
| | | from | 217 | | |
Abstract
One of the challenges facing formulation scientists is the development of site specific delivery systems capable of releasing the active ingredient in the lower part of the small intestine and/or colon. Development of colon specific drug delivery systems can enhance the treatment of colonic conditions such as ulcerative colitis (UC), Crohn’s disease (CD) and colorectal cancer (CRC). Colon targeted drug delivery systems (CTDDS)have the potential to reduce side effects and increase pharmacological response with low drug concentration. Recent studies proved the efficiency of celecoxib (CXB) for the treatment of inflammatory bowel diseases (IBD). CXB is a selective cyclooxygenase (COX)-2 inhibitor used as a non-steroidal anti-inflammatory drug with less gastrointestinal side effects compared to non-selective COX inhibitors. However, COX-2 inhibitors promote thrombosis and substantially increase the risk of heart attack at high doses after systemic administration.Being a Biopharmaceutical classification system (BCS) class II drug, it suffers from poor bioavailability (22-40%) caused by its low water solubility (3.3 æg/mL). Due to the colon low fluid volume, it will be more difficult to dissolve CXB in the colon